REFERENCES
- Wakelee H., Change E., Gomez S., et al. Lung cancer incidence in never smokers. Jrnl. Clin. Oncol. 2007; 25: 472–478
- Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancer from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. 2004; 101: 13306–13311
- Shepherd F., Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small cell lung cancer. NEJM 2005; 353: 123–132
- Toh C., Gao F., Lim W., et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J. Clin. Oncol. 2006; 24: 2245–2251
- The Elderly Lung cancer Vinorelbine Italian Study group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999; 85: 365–76
- Gridelli C., Perronet F., Gallo C., et al. Chemotherpay for elderly patients with non-small cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J. Natl. Cancer Inst. 2003; 95: 362–37
- Langer C. J., Manola J., Bernardo P., et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J. Natl. Cancer Inst. 2002; 94: 173–18
- Kelly K., Giarritta S., Hayes S., et al. Should older patients receive combination chemotherapy for advanced non-small cell lung cancer? An analysis of the Southwest Oncology Trials 9509 and 9308. Proc. Am. Soc. Clin. Oncol. 2001; 329a, (abstr #1313)
- Lilenbaum R. C., Herndon J., List M., et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life and cost-effectiveness. J. Clin. Oncol. 2005; 23: 190–196
- Hesketh P., Chansky K., Lau D., et al. Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027). J. Thoracic. Oncol. 2006; 1: 537–544
- Lilenbaum R., Rubin M., Joyce S., et al. A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer. J. Thoracic. Oncol. 2007; 2: 306–311
- David Jackman M., Beow Yeap Y., Neal Lindeman I., et al. Phase II Clinical Trial of Chemotherapy-Naïve Patients 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer. J. Clin. Oncol. 2007; 25: 760–766
- Sweeney C., Zhu J., Sandler A. B., et al. Outcome of performance status 2 patients in E1594, a phase III trial in metastatic non-small cell lung cancer. Cancer 2001; 92: 2639–266
- Tester W. J., Stephenson P., Langer C. J., et al. ECOG 1599: Randomized phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status 2 patients with advanced non-small cell lung cancer. PASCO 2004; 23: 627, (abstract 7055)
- Lilenbaum R., Axerold R., Thomas S., et al, Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2
- Parkin D. M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005; 55: 74–108
- Hirsch F. R., Merrick D. T., Franklin W. A. Role of biomarkers for early detection of lung cancer and chemoprevention. Eur. Respir. J. 2002; 19: 1151–1158
- Auerbach O., Hammond E. C., Kirman D., Garfinkel L. Effects of cigarette smoking on dogs. II. Pulmonary neoplasms. Arch. Environ. Health 1970; 21: 754–768
- Wistuba I. I., et al. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. 1997; 89: 1366–1373
- Franklin W. A., et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J. Clin. Invest. 1997; 100: 2133–2137
- Guo M., et al. Promoter hypermethylation of resected bronchial margins: a field defect of changes?. Clin. Cancer Res 2004; 10: 5131–5136
- Miyazu Y. M., et al. Telomerase expression in noncancerous bronchial epithelia is a possible marker of early development of lung cancer. Cancer Res. 2005; 65: 9623–9627
- Spira A., et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc. Natl. Acad. Sci. USA 2004; 101: 10143–10148
- Spira A., Beane J., Shah V., Steiling K., Liu G., Schembri F., Gilman S., Dumas Y., Calner P., Sebastiani P., Sridhar S., Beamis J., Lamb C., Keane J., Lenburg M., Brody J. Airway Epithelial Gene Expression in the Diagnostic Evaluation of Smokers with Suspect Lung Cancer. Nat Med. 2007; 13: 361–366